Tyrosine kinase signalling in breast cancer. Insulin-like growth factors and their receptors in breast cancer

Breast Cancer Research

Volumn 2, Issue 3, 2000, Pages 170-175

  Zhang, X ^a   Yee, D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Insulin like growth factor; Insulin like growth factor receptor; Signal transduction

Indexed keywords

ESTROGEN RECEPTOR; INTEGRIN RECEPTOR; RECEPTOR SUBTYPE; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TYROSINE KINASE RECEPTOR;

AUTOPHOSPHORYLATION; BIOCHEMISTRY; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; HUMAN; HUMAN CELL; MAMMAL CELL; METASTASIS; MOLECULAR INTERACTION; PHYSIOLOGY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 0034469081     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr50     Document Type: Review

References (81)

1. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations
2. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
3. Insulin-like growth factor II mRNA expression in human breast cancer
4. Expression of IGF-I and IGF-II mRNA in breast tissue
5. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study
6. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily
7. Insulin-like growth factor binding proteins: New proteins, new functions
8. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells
9. Insulin-like growth factor II receptor as a multifunctional binding protein
10. The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor
11. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid
12. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3)
13. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
14. Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors
15. Molecular and cellular aspects of the insulin-like growth factor I receptor
16. The IRS-1 signaling system
17. Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2
18. Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation [In Process Citation]
19. Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells
20. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
21. Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor
22. Interaction of p85 subunit of Pl 3-kinase with insulin and IGF-I receptors analysed by using the two-hybrid system
23. Grb10: A new substrate of the insulin-like growth factor I receptor
24. P125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors
25. C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor
26. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3′-kinase
27. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1
28. Role of IRS-1 GRB-2 complexes in insulin signaling
29. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: Implications for insulin control of ras signaling
30. The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp
31. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells
32. The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling
33. Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src
34. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance
35. Insulin and insulin-like growth factor-1 stimulate dephosphorylation of paxillin in parallel with focal adhesion kinase
36. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study
37. Stromal IGF-II messenger RNA in breast cancer: Relationship with progesterone receptor expressed by malignant epithelial cells
38. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function
39. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
40. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention
41. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
42. Type 1 IGF receptor in human breast diseases
43. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
44. Insulin-like growth factor-I (IGF-I) receptors in breast cancer
45. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
46. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism
47. Insulin and insulin-like growth factor-I(IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling
48. M6P/IGF2 receptor: A candidate breast tumor suppressor gene
49. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations
50. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
51. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol
52. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
53. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
54. Cloning of the human oestrogen receptor cDNA
55. Cloning of a novel receptor expressed in rat prostate and ovary
56. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
57. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
58. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen
59. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes
60. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
61. Enhancement of Insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
62. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
63. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
64. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells
65. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity
66. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
67. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
68. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
69. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors
70. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells
71. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
72. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells
73. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death: Proliferative and anti-apoptotic effects
74. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
75. Association of insulin receptor substrate-1 with integrins
76. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor
77. Blocking ligand occupancy of the alphaV beta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells
78. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells
79. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor I (IGF-I) in human breast cancer cell lines
80. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin
81. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer